Revolution Medicines Inc (RVMD) Actualités

Form 3 - Initial statement of beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 8-K - Current report

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 8-K - Current report

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...